Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 26, 2025; 13(12): 98768
Published online Apr 26, 2025. doi: 10.12998/wjcc.v13.i12.98768
Published online Apr 26, 2025. doi: 10.12998/wjcc.v13.i12.98768
Corticosteroids in posterior reversible encephalopathy syndrome: Friend or foe? A systematic review
Bahadar S Srichawla, Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01655, United States
Taranjit Kaur, Department of Medicine, William Carey University College of Osteopathic Medicine, Hattiesburg, MS 39401, United States
Harsimran Singh, Department of Medicine, University of California Berkeley, Berkeley, CA 94720, United States
Author contributions: Srichawla BS was responsible for writing and editing of the manuscript, data collection, synthesis, analysis, intellectual conceptualization, and visualization of graphs; Kaur T and Singh H were responsible for data collection.
Conflict-of-interest statement: The authors report no conflicts of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bahadar S Srichawla, DO, MS, Staff Physician, Department of Neurology, University of Massachusetts Chan Medical School, 55 Lake Ave N, Worcester, MA 01655, United States. bahadar.srichawla@umassmed.edu
Received: July 4, 2024
Revised: October 24, 2024
Accepted: December 17, 2024
Published online: April 26, 2025
Processing time: 186 Days and 9.6 Hours
Revised: October 24, 2024
Accepted: December 17, 2024
Published online: April 26, 2025
Processing time: 186 Days and 9.6 Hours
Core Tip
Core Tip: Posterior reversible encephalopathy syndrome (PRES) is characterized by headaches, seizures, confusion, and visual disturbances due to endothelial dysfunction and vasogenic edema. Corticosteroids have a dual role in PRES, potentially inducing the condition through hypertension while also treating it by reducing inflammation and stabilizing the blood-brain barrier. This systematic review identifies 57 cases of corticosteroid-induced PRES and 14 cases where corticosteroids were used therapeutically. Understanding this dual role is crucial for optimizing patient care, highlighting the need for careful monitoring and tailored treatment strategies.